Related by context. All words. (Click for frequent words.) 76 ApoB SNALP 75 ALN PCS 74 TKM ApoB 71 PEG SN# 71 AQ4N 71 TOCOSOL Paclitaxel 71 Panzem R 71 EndoTAG TM -1 71 INCB# [001] 71 TKM PLK1 71 MEK inhibitor 70 R#/MEM # 70 investigational humanized monoclonal antibody 70 Solazed TM 70 elotuzumab 70 Solazed 70 Belinostat 70 ALN VSP 70 Phase #b/#a clinical 70 IMA# 70 mitogen activated ERK kinase 70 oral prodrug 70 lintuzumab SGN 69 Panzem R NCD 69 trastuzumab DM1 T DM1 69 Archexin 69 Androxal TM 69 targeted radiotherapeutic 69 DOS# 69 Alnylam #x# 69 SinuNase ™ 69 telomerase inhibitor drug 69 Neuradiab 69 XP# XP# 69 Azedra 69 alvespimycin 69 HCD# [002] 69 JAK inhibitor 69 custirsen 69 Zemiva TM 69 FOLOTYN ® 69 delivers fluocinolone acetonide FA 69 Curaxin 69 PDX pralatrexate 68 MAXY G# 68 Allovectin 7 68 CD# CEA 68 IgG1 monoclonal antibody 68 PrevOnco ™ 68 GVAX ® 68 Xcytrin R 68 ridaforolimus 68 hypoxia activated prodrug 68 CCX# 68 HGS ETR2 68 DPX Survivac 68 Panzem 68 Onconase 68 Factor VIIa 68 MyVax R 68 Onco TCS 68 anticancer compound 68 EVIZON TM squalamine lactate 68 novel histone deacetylase 68 PSMA ADC 68 ALN TTR 68 MGCD# [001] 68 candidate REP# 68 MOZOBIL 68 PDE4 inhibitor 68 OvaRex R 68 Romidepsin 68 Protexia ® 68 dacetuzumab SGN 68 orally administered inhibitor 68 PF # [002] 68 molecular imaging radiopharmaceutical 68 Anturol ® 68 acyclovir Lauriad R 68 CEQ# 68 Trofex 68 vosaroxin 68 KNS # 68 ANYARA 67 telomerase therapeutic 67 evaluating satraplatin 67 selective androgen receptor modulator 67 IMC #B 67 candidate AQ4N 67 HDL Mimetic Peptide 67 oral ridaforolimus 67 Iluvien ® 67 rxRNA 67 huC# DM4 67 forodesine 67 ONCONASE R 67 mertansine 67 ILUVIEN ® 67 phase IIa clinical 67 Completes Patient Enrollment 67 IND submission 67 polysaccharide polymer 67 BiTE antibody 67 Generx TM 67 HGS ETR1 67 PORxin TM 67 Dendreon investigational 67 investigational monoclonal antibody 67 Sym# 67 Personalized Immunotherapy 67 ELACYT 67 Cloretazine ® 67 Surfaxin LS 67 acetonide FA 67 candidate CRLX# 67 AEG# 67 XOMA 3AB 67 Allovectin 7 r 67 PREOS R 67 deforolimus 67 TELINTRA 67 histone deacetylase HDAC inhibitor 67 ASONEP TM 67 Fibrillex TM 67 Civacir 67 IL# PE#QQR 67 teduglutide 67 Cintredekin Besudotox 67 XL# XL# 67 Allovectin 7 R 67 PNP inhibitor 67 Troxatyl 67 metaglidasen 67 Soliris eculizumab 67 HCV protease inhibitor 67 Zenvia ™ 67 GLP toxicology studies 67 dextromethorphan quinidine 67 BiovaxID TM 67 BCX# 67 phase IIb clinical 67 Marqibo TM 67 AzaSite Plus 67 R sorafenib tablets 66 TELINTRA R 66 CB2 selective receptor agonist 66 MAGE A3 ASCI 66 ATL# [001] 66 motexafin gadolinium Injection 66 HuLuc# 66 Bezielle 66 Phase Ib clinical trials 66 TOCOSOL Camptothecin 66 Omigard 66 PI3K/Akt pathway inhibitor 66 SNS# T 66 tafamidis 66 XL# anticancer compounds 66 Amrubicin 66 Zemiva ™ 66 Hematide ™ 66 RGB # 66 Canvaxin TM 66 leading oral taxane 66 non nucleoside HCV 66 Phase IIb clinical trials 66 Chemokine Therapeutics 66 Perifosine 66 CR# vcMMAE 66 SinuNase TM 66 oral proteasome inhibitor 66 SNALP technology 66 oncolytic virus therapies 66 therapeutic monoclonal antibody 66 UVIDEM 66 Tesetaxel 66 Soliris TM eculizumab 66 Lenocta 66 including eniluracil ADH 66 IND enabling 66 liposomal formulation 66 glufosfamide 66 Azedra TM 66 ASONEP 66 CCR5 mAb 66 Chemophase 66 Aurexis 66 Tarmogen 66 PS# [001] 66 Fx #A 66 XL# XL# XL# XL# 66 Biologic License Application BLA 66 ALTROPANE R 66 Aganocide 66 IV APAP 66 torezolid phosphate 66 candidate XP# 66 Aflibercept 66 TBC# 66 Urocidin TM 66 Virulizin R 66 Exherin TM 66 PXD# 66 thymalfasin 66 sapacitabine CYC# 66 Daclizumab 66 ocular formulation 66 DAVANAT R 66 tezampanel 66 Bicifadine 66 PEG PAL 66 Intermezzo ® zolpidem tartrate 66 RNAi Therapeutic 66 nalbuphine ER 66 AP# [003] 66 DXL# 66 Alzhemed TM 66 Phase 1b clinical trials 66 JAK1 66 Angiocept 66 IAP inhibitors 66 Fodosine 65 OncoVEX GM CSF 65 tanespimycin 65 LE DT 65 tramiprosate ALZHEMED TM 65 Nanobody 65 Panzem NCD 65 modified glutathione analog 65 Asentar 65 Meets Primary Endpoint 65 LEP ETU 65 oral picoplatin 65 recombinant biopharmaceutical 65 Squalamine 65 Synavive 65 THALOMID 65 Omacetaxine 65 Onalta 65 LibiGel ® 65 OXi# 65 PHX# 65 tezampanel NGX# 65 OvaRex ® MAb 65 virus HCV protease inhibitor 65 StaphVAX R 65 Genasense ® oblimersen 65 Pruvel 65 pralatrexate 65 MKC# MT 65 Alfacell proprietary ribonuclease 65 ALN TTR# 65 Xanafide 65 MYDICAR ® 65 Chrysalin 65 Proellex TM 65 VEGF Trap 65 talactoferrin 65 Vandetanib 65 Altropane 65 RIGScan CR 65 sorafenib tablets 65 lexidronam injection 65 sodium Injection 65 PRT# 65 drug conjugate 65 squalamine 65 Nanobody R 65 DAVANAT ® 65 topically applied SEPA 65 LymphoStat B TM 65 ARRY # 65 TKB# 65 Golimumab 65 clinical trials dacetuzumab SGN 65 CORT # 65 Azedra ™ 65 HQK 65 preclinical efficacy 65 Homspera TM 65 volociximab 65 PEGPH# 65 L BLP# 65 GED aPC 65 MT#/MEDI-# 65 ORENCIA R 65 Shigamabs ® 65 THR beta agonist 65 Evoltra ® 65 Ocrelizumab 65 AAG geldanamycin analog 65 eniluracil 65 Phase 2a clinical trials 65 MAXY alpha 65 dacetuzumab 65 Spiegelmer ® 65 Guanilib 65 CYT# potent vascular disrupting 65 Zemiva TM Trofex TM 65 PROVENGE ® 65 MT# MEDI 65 IAP inhibitor 65 HDL Selective Delipidation 65 SUCCEED trial 65 PANVAC VF 65 Saforis 65 HepeX B 65 adecatumumab MT# 65 MEK inhibitor RDEA# 65 KRN# 65 Excellarate 65 CINTREDEKIN BESUDOTOX 65 Trofex TM 65 epothilones 65 CORLUX CORT # 65 cMET 65 Pivotal Phase 65 atacicept 65 Corlux 65 Virulizin ® 65 BLA submission 65 LE SN# 65 Phase IIa trials 65 PrevOnco 65 Elesclomol 65 tiapamil 65 Phase Ib 65 EndoTAG TM 65 Phase #/#a trial 65 vilazodone 65 Nexavar ® 65 encapsulates siRNAs 65 Dalbavancin 65 multi kinase inhibitor 65 candidate deforolimus 65 ThermoDox ® clinical 65 bafetinib 65 antibody MAb 65 otelixizumab 64 Initiates Phase II 64 Initiates Enrollment 64 ganetespib 64 YONDELIS 64 cinacalcet HCl 64 HepeX B TM 64 investigational pan BCR 64 Hedgehog Pathway Inhibitor 64 LymphoStat B 64 Cloretazine R VNP#M 64 Targeted Chemotherapy 64 Phase III Clinical Trial 64 Phenoptin 64 initiated Phase Ib 64 Kosan dependence 64 Virulizin 64 GRN#L 64 hormone LHRH antagonist 64 CAMPATH 64 ORE# 64 registrational trial 64 trastuzumab DM1 64 GVAX R 64 AN# novel 64 XmAb 64 ENMD # 64 JAK2 inhibitor 64 Hsp# Inhibitor 64 BEMA TM Fentanyl 64 Tezampanel 64 OMP #M# 64 neratinib 64 ospemifene 64 docetaxel Taxotere R 64 ONCONASE 64 systemic RNAi therapeutic 64 BLA filing 64 octreotide implant 64 Vicinium TM 64 class mGluR5 inhibitor 64 proteasome inhibitor 64 Icatibant 64 Trofex ™ 64 radiation sensitizer 64 Initiates Phase III 64 Aurora kinase inhibitor 64 TRAIL receptor antibodies 64 Myocet 64 AeroLEF TM 64 isoform selective 64 epothilone 64 novel VDA molecule 64 Dacogen injection 64 APF# 64 M# rationally 64 seliciclib CYC# 64 HDAC Inhibitor 64 Oral Calcitonin 64 Phase 2b Clinical Trial 64 RDEA# 64 EOquin 64 RhuDex ® 64 EOquin TM 64 targets Galectin receptors 64 Pivotal Phase III 64 ALN HPN 64 PNT# 64 JAK2 Inhibitor 64 non nucleoside inhibitor 64 JOULFERON 64 Prednisporin TM 64 LentiVector technology 64 initiated Phase 1b 64 Unit Dose Budesonide 64 NPC 1C 64 Tarvacin TM 64 Presents Preclinical Data 64 apoptosis inducer 64 therapeutic monoclonal antibodies 64 TKM Ebola 64 romidepsin novel 64 immunotherapeutic agent 64 PEG Interferon lambda 64 Phase 2b clinical trials 64 HuMax TAC 64 Talabostat 64 Telatinib 64 TREANDA 64 Carfilzomib 64 Neo Urinary Conduit 64 registrational 64 MCSP respectively 64 Insegia 64 entinostat 64 Amigal 64 rNAPc2 64 Genasense R oblimersen 64 Proxinium TM 64 Gemzar ® 64 HGS# 64 Glybera 64 velafermin belinostat 64 Bellicum Pharmaceuticals Inc. 64 MOR# 64 HuCAL antibodies 64 MKC# MKC# PP 64 BRIM2 64 HGS ETR1 mapatumumab 64 ZEVALIN ® 64 lintuzumab 64 ® bortezomib 64 GATTEX ® 64 OncoVEX 64 Prednisporin 64 IMPDH inhibitor 64 E1 INT TM 64 indibulin 64 OMP #R# 64 cancer immunotherapies 64 SNT MC# 64 IMiDs R 64 Files Investigational 64 glucokinase activator 64 ularitide 64 obatoclax 64 refractory chronic lymphocytic 64 targeted antifolate 64 Ecallantide 64 Veronate 64 Ganite ® 64 topical antifungal product 64 RAPTIVA r 64 Hematide TM 64 Temsirolimus 64 torsemide ER 64 GERD migraine headaches 64 TELCYTA 64 ELND# 64 MAXY VII 64 UPLYSO 64 EndoTAGTM 1 64 ADVEXIN p# therapy 64 confirmatory Phase 3 64 confirmatory Phase III 64 Cleviprex TM clevidipine 64 Stedivaze 64 Zybrestat 64 Phase Ib study 64 ® decitabine 64 CCR9 antagonist 64 MEK Inhibitor 64 PRECISE trial 64 CTAP# Capsules 64 Nanobody ® 64 Anturol TM 64 AKT inhibitor 64 Arimoclomol 64 Augment TM 64 generation URAT1 inhibitor 64 Mpex 64 CRMD# 64 pradefovir 64 Xcellerated T Cells 64 XYOTAX TM 64 Canvaxin 63 Prestara 63 therapeutic peptide 63 pan HDAC inhibitor 63 Phase IIb clinical 63 Cellegesic 63 IRX 2 63 LEVADEX TM 63 MGd 63 GATTEX TM 63 Inhalation Solution 63 Diamyd ® 63 Pimavanserin 63 GRNVAC1 63 include PLX IBD 63 Oral NKTR 63 Telik logo TELINTRA 63 RNAi therapeutic targeting 63 Optiquel ™ 63 Maribavir 63 Milestone Payments 63 ZK EPO 63 Anturol 63 investigational therapies 63 Phase III Pivotal 63 TAFA# 63 Phase IIIb clinical 63 LEUKINE 63 novel peptide 63 3 registrational trial 63 Cloretazine 63 Phase #b/#a 63 Initiate Phase 63 Exelixis compounds 63 alpha folate receptor 63 eltrombopag 63 overactive bladder AA# 63 severe hypercholesterolemia 63 Randomized Phase 63 BHT DNA 63 opioid induced bowel dysfunction 63 VitiGam 63 ARIKACE ™ 63 aflibercept 63 GLPG# 63 Adenosine Therapeutics 63 Exherin 63 Matrix Phase 2b 63 Quinamed 63 Sudhir Agrawal D.Phil 63 dutogliptin 63 vascular disrupting agents 63 Sulonex 63 M Enoxaparin 63 pralatrexate injection folate analogue 63 Reports Preclinical Data 63 EP #R 63 personalized immunotherapy 63 Alocrest 63 Somatuline Depot 63 Varespladib 63 gastro intestinal inflammation 63 RenaZorb TM 63 clinical trials SGN 63 Empatic ™ 63 Pradefovir 63 targeting Inflammatory Bowel 63 ALN HTT 63 Tanespimycin 63 IMiDs 63 Phase Ib clinical 63 PSN# [002] 63 HspE7 63 synthetic retinoid 63 highly purified pasteurized 63 Polymer Microspheres 63 Phase 1a clinical 63 Exelixis XL# 63 Asentar TM 63 lumiliximab 63 #D#C# 63 PROSTVAC VF 63 alvimopan 63 GRN# 63 Phase IIb Clinical Trial 63 interferon gamma 1b 63 Protexia R 63 NDA Submission 63 product platforms AZX# 63 successfully commercialize Iluvien 63 candidate TNFerade biologic 63 stable nucleic acid 63 TRO# 63 tubulin inhibitor 63 Familial Adenomatous Polyposis FAP 63 midstage trials 63 novel immunotherapies 63 Phase IIa clinical trials 63 Besivance 63 Oracea TM 63 MORAb 63 DexaSite 63 mocetinostat MGCD# 63 Cloretazine R 63 Phase 2b clinical 63 agonistic human 63 Glybera R 63 compound INCB# 63 T Pred 63 CDK cyclin dependent 63 lorvotuzumab mertansine 63 ADVEXIN clinical 63 ThermoDox R 63 Liprotamase 63 NEBIDO R 63 product candidate Lpathomab 63 ATPace TM 63 TLK# 63 liprotamase 63 trastuzumab Herceptin R 63 faropenem 63 Relivar 63 Micromet proprietary BiTE 63 Davanat 63 sargramostim 63 incyclinide 63 Ozarelix 63 compound PMX # 63 Glufosfamide 63 Mipomersen 63 Syncria 63 Trastuzumab DM1 63 Ophthotech 63 Annamycin 63 Cardio Vascu Grow 63 Nasulin ™ 63 Onalta ™ 63 preclinical 63 MAA submission 63 RECOTHROM R 63 CRLX# 63 PGL# 63 PORxin TM platforms 63 Hybridon 63 MDV# 63 preclinically 63 candidates bavituximab 63 Thelin TM 63 Phase Ib IIa 63 paclitaxel Taxol ® 63 Phase Ib II 63 Intravenous CP 63 IV Busulfex 63 Preclinical studies suggest 63 Chimigen TM 63 Prodarsan R 63 tosedostat 63 oral Hsp# inhibitor 63 subcutaneous formulation 63 Initiates Clinical 63 XmAb ® 63 systemic RNAi 63 Orathecin 63 Thiarabine 63 InterfeRx 63 Phase IIb trials 63 XL# XL# XL# 63 Cetrorelix 63 candidate ridaforolimus 63 Aganocide ® 63 CoFactor 63 antibody MT# 63 Sphingomab TM 63 TOCOSOL R 63 INSPIRE Trial Phase III 63 ISIS # 63 TransVax TM 63 selective immunoproteasome inhibitor 63 Thalomid ® 63 faropenem medoxomil 63 Receives Fast Track 63 MorphoSys proprietary 63 EVIZON TM 63 TACI Ig 63 Begins Dosing 63 Acetavance TM intravenous acetaminophen 63 vaccines oncolytic virus 63 Eniluracil 63 LymphoStat B belimumab 63 enzastaurin 63 dasatinib Sprycel ® 63 vidofludimus 63 triphendiol 63 BAY #-# 63 Combination REOLYSIN R 63 drug pipeline TAFA# 63 RNAi therapeutic 63 PROSTASCINT R 63 nonclinical studies 63 Kuvan TM sapropterin 63 MYDICAR 63 GAP #B# 63 Tyrima 63 erlotinib Tarceva ® 63 trodusquemine MSI 63 JZP 63 Anidulafungin 63 Antibody Drug Conjugate 63 NEUMUNE 63 Cx# [002] 62 OMS#HP 62 MEND CABG II 62 Auxilium transmucosal film 62 Plicera 62 Panitumumab 62 ICA # 62 diagnostic radiopharmaceutical 62 Targretin capsules 62 candidate Zenvia 62 ZADAXIN ® 62 PCK# 62 BRAF inhibitor 62 NP2 Enkephalin 62 sirtuin modulators 62 Memryte 62 TLR9 agonist IMO 62 oral methylnaltrexone 62 platforms GVAX 62 preclinical pharmacokinetic 62 REOLYSIN ® 62 inhaled AAT 62 Aplidin 62 TRX1 62 HuCNS SC ® 62 BrachySil TM 62 immunosuppressive compound 62 Otelixizumab 62 Excellarate TM 62 ZFP Therapeutics 62 accumulate preferentially 62 personalized cellular immunotherapy 62 RAV# 62 EXPAREL TM 62 R#/MEM 62 ZEGERID Capsules 62 Aryplase 62 ZOLINZA 62 Ixempra 62 BYETTA ® 62 SPL# Gel vaginal microbicide 62 peginesatide 62 CBLC# 62 Marqibo 62 rheumatoid arthritis thrombocytopenia 62 Daniel Junius 62 UltiMAb 62 HCV nucleoside polymerase inhibitors 62 Atiprimod 62 ruxolitinib 62 Actimmune ® 62 Adnectin 62 Rebif ® 62 Dyloject TM 62 Stimuvax R 62 INS# [001] 62 preclinical toxicology 62 next generation URAT1 62 sunitinib malate 62 PSN# [001] 62 telaprevir VX 62 metastatic hormone refractory 62 KRYSTEXXA TM pegloticase 62 CYT# vascular disrupting 62 Aviptadil 62 Neo Kidney Augment 62 Elagolix 62 MyVax ® 62 lenalidomide Revlimid R 62 huN# DM1 62 rhMBL 62 MAP# 62 Ridaforolimus 62 Maxy G# 62 Pralatrexate 62 Charlesson 62 Rigel R# 62 Phase IIB 62 TRIOLEX HE# APOPTONE HE# 62 MNTX 62 Aplidin R 62 Locteron ® 62 Announces Poster Presentations 62 L DOS# 62 Phase lll 62 Curaxin CBLC# 62 Anthim 62 depsipeptide 62 selective angiogenic kinase inhibitor 62 Solazed ™ 62 GALNS 62 Metastatic Melanoma 62 apricitabine ATC 62 Sopherion 62 CTCE 62 AzaSite TM 62 diarrhea predominant irritable 62 FavId 62 Sulonex TM 62 SAR# [004] 62 IIa trial 62 Intarcia 62 Novolimus 62 BRIM3 62 TLR9 agonists 62 BENLYSTA ® 62 sodium thiosulfate STS 62 Nasulin 62 lead molecular radiotherapeutic 62 maribavir 62 Aurora Kinase 62 Lenocta TM 62 include Phenoptin TM 62 CUDC 62 axitinib 62 Prodarsan ® 62 Posiphen 62 HER2 positive metastatic breast 62 hematological indications 62 REG1 Anticoagulation System 62 DCVax R 62 Ceflatonin R 62 Crofelemer budesonide foam 62 TOCOSOL 62 Loramyc R 62 DIFICID ™ 62 RAPTIVA R 62 ionotropic glutamate receptor antagonists 62 receptor tyrosine kinase inhibitor 62 ATL# [002] 62 Neupogen ® 62 candidate MyVax 62 Anavex #-# 62 oxybutynin ATD TM 62 Earns Milestone Payment 62 MAb therapy 62 novel therapeutic antibodies 62 Fibrin Pad 62 ONTAK 62 Darinaparsin 62 Iloperidone 62 protein kinase inhibitor 62 inflammatory autoimmune diseases 62 selective kinase inhibitor 62 Vicriviroc 62 Complete Response 62 Neo Kidney Augment ™ 62 Genasense ® 62 rALLy clinical trial 62 SUPPRELIN R LA 62 pivotal Phase III 62 Restanza 62 TRANSDUR ® 62 Zelrix 62 Neulasta ® 62 BENLYSTA 62 HepDirect 62 Oncaspar 62 Vectibix panitumumab 62 protein tyrosine phosphatase 1B 62 PRX # 62 Potelligent Technology 62 Bellicum 62 R lenalidomide 62 EFAPROXYN 62 TRANSDUR Sufentanil 62 Phase 2a Clinical Trial 62 LHRH antagonist 62 Hematide ™ peginesatide 62 Nexavar sorafenib 62 brentuximab 62 Bortezomib 62 Azedra TM Onalta TM 62 forodesine hydrochloride 62 CIP TRAMADOL ER 62 Azixa 62 Theratope 62 TOLAMBA 62 pertuzumab 62 metastatic carcinoid 62 AZD# 62 CIP ISOTRETINOIN 62 SILENOR TM 62 orally bioavailable 62 AERx iDMS 62 humanized monoclonal antibodies 62 belinostat 62 anti CD3 monoclonal 62 Vion Pharmaceuticals 62 Voreloxin 62 hypoxia selective 62 omacetaxine mepesuccinate 62 herpetic keratitis 62 Sangamo BioSciences Announces 62 dirucotide 62 ENTEREG ® 62 ZFNs clinical trials 62 punctal plug 62 Zingo TM 62 AIMM trial 62 Phase III clinical 62 compound AEOL # 62 pseudobulbar affect PBA 62 6R BH4 62 generation purine nucleoside 62 siRNA therapeutic 62 Generx ™ 62 generation antisense 62 MTP inhibitor 62 hepatitis C polymerase inhibitor 62 Phase 2a trial 62 Hsp# inhibitor 62 P#X# antagonist 62 CA4P 62 non porcine pancreatic 62 ADVEXIN 62 R roscovitine 62 vascular disrupting agent 62 Files IND 62 sarcoma melanoma 62 2 inhibitor CYT# 62 Fleximer 62 budesonide foam 62 Trodusquemine MSI 62 XL# [003] 62 rALLy 62 selective estrogen receptor modulator 62 vernakalant oral 62 investigational antiplatelet agent 62 Tesmilifene 62 ABL inhibitor 62 HCV protease inhibitors 62 tolevamer 62 Presents Preclinical 62 treat refractory angina 62 Initiate Clinical Trial 62 Æterna Zentaris 62 phase IIa 62 VQD 62 HEPLISAV ™ 62 lomitapide 62 ATL/TV# 62 Myrexis 62 assessing T DM1 62 NV1FGF 62 relapsed leukemia 62 rhThrombin 62 HuMax EGFr 62 novel emulsion formulation 62 Genz # 62 ENMD 62 humanized anti 62 microtubule inhibitor 62 midstage clinical 62 TNFerade ™ 62 TRANSDUR ™ 62 vaccine GRNVAC1 62 reslizumab 62 Genitope Corporation 62 #ME# 62 methylnaltrexone 62 Phase 2a clinical 62 recurrent metastatic ovarian cancer 62 ELADUR 62 Novel Oral 62 drug GAP #B# 62 monoclonal antibody conjugated 62 multicenter Phase II 62 Pertuzumab 61 oral isoform selective HDAC 61 Hyphanox 61 BRILINTA 61 FDA Approvable Letter 61 beta 1a 61 R sipuleucel T 61 autologous cellular immunotherapy 61 QNEXA 61 Successfully Completes Phase 61 5 fluorouracil leucovorin 61 Hsp# inhibition 61 TransVax tm 61 R bortezomib 61 sumatriptan DosePro 61 Allovectin 7 ® 61 selective GR 61 Acetavance TM 61 HuMax CD4